TP53 and ovarian cancer: In cell culture studies, SHetA2 and PRIMA-1MET synergistically inhibited ovarian cancer cell line growth with greater effects in cell lines harboring missense mutant p53 and no significant drug interaction in healthy fallopian tube cell cultures.